Trial Profile
A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Milvexian (Primary) ; Aspirin; Clopidogrel
- Indications Atherosclerosis; Brain infarction; Stroke; Transient ischaemic attacks
- Focus Proof of concept; Therapeutic Use
- Acronyms AXIOMATIC-SSP
- Sponsors Bristol-Myers Squibb
- 01 Jan 2024 Results reporting efficacy and safety data published in the Lancet Neurology
- 06 Oct 2022 Status changed from active, no longer recruiting to completed.
- 28 Aug 2022 According to a Bristol-Myers Squibb media release, results from this trial were presented in a Hot Line session at the European Society of Cardiology (ESC) Congress 2022.